Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study

BACKGROUND: Treatment of MS often begins with low-efficacy injectable disease-modifying therapy (iDMT). OBJECTIVES: To compare the effect of fingolimod 0.5 mg/day on clinical, MRI, patient-reported, and safety outcomes, in treatment-naïve and previously treated (≥1 iDMT) patients with early MS. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández, Oscar, Izquierdo, Guillermo, Aguera, Eduardo, Ramo, Cristina, Hernandez, Miguel, Silva, Diego, Walker, Rob, Butzkueven, Helmut, Wang, Chenyu, Barnett, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493256/
https://www.ncbi.nlm.nih.gov/pubmed/32974041
http://dx.doi.org/10.1177/2055217320957358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493256/
https://www.ncbi.nlm.nih.gov/pubmed/32974041
http://dx.doi.org/10.1177/2055217320957358

Ejemplares similares